Boston Scientific Announces Results for Third Quarter Ended Septembe...( NATICK Mass. Oct. 19 /- Boston Sc...)

NATICK, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2007, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter of 2007.

Highlights

- Reported net sales of $2.048 billion, which was at the mid-point of

guidance, and adjusted EPS of $0.20, which exceeded guidance

- Attained number one position in the worldwide drug-eluting stent (DES)

market

- Achieved DES market share leadership in Japan

- Reached 56 percent market share in the U.S. DES market, up from

54 percent last quarter

- Reported year-over-year worldwide cardiac rhythm management (CRM) sales

growth of 16 percent, including implantable cardioverter defibrillator

(ICD) growth of 18 percent

- Announced several new initiatives designed to increase shareholder

value, including the planned sale of business units, and expense and

head count reductions

- Amended the Company's term loan agreement, providing increased

financial flexibility, while prepaying $1 billion of the loan

Net sales for the third quarter of 2007 were $2.048 billion as compared to $2.026 billion for the third quarter of 2006. Worldwide sales of the Company's drug-eluting coronary stent systems for the third quarter of 2007 were $448 million as compared to $572 million for the third quarter of 2006. U.S. sales of drug-eluting coronary stent systems for the third quarter of 2007 were $240 million as compared to $384 million for the third quarter of 2006. International sales of drug-eluting coronary stent systems were $208 milli
'/>"/>